Eberhard Schatz

502 total citations
25 papers, 232 citations indexed

About

Eberhard Schatz is a scholar working on Epidemiology, Hepatology and General Health Professions. According to data from OpenAlex, Eberhard Schatz has authored 25 papers receiving a total of 232 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Epidemiology, 15 papers in Hepatology and 5 papers in General Health Professions. Recurrent topics in Eberhard Schatz's work include Hepatitis C virus research (15 papers), HIV, Drug Use, Sexual Risk (13 papers) and Hepatitis B Virus Studies (11 papers). Eberhard Schatz is often cited by papers focused on Hepatitis C virus research (15 papers), HIV, Drug Use, Sexual Risk (13 papers) and Hepatitis B Virus Studies (11 papers). Eberhard Schatz collaborates with scholars based in Spain, Netherlands and Denmark. Eberhard Schatz's co-authors include Jeffrey V. Lazarus, Mojca Matičič, Marianne Jauncey, Allison M. Salmon, Vendula Běláčková, Erika Duffell, Marta Torrens, Magdalena Harris, Tuukka Tammi and Stanislas Pol and has published in prestigious journals such as SHILAP Revista de lepidopterología, Nature Reviews Gastroenterology & Hepatology and BMC Medicine.

In The Last Decade

Eberhard Schatz

25 papers receiving 228 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eberhard Schatz Spain 10 183 126 47 37 35 25 232
Martin Kåberg Sweden 9 260 1.4× 168 1.3× 48 1.0× 67 1.8× 37 1.1× 25 285
Anna Palmer Australia 10 158 0.9× 93 0.7× 62 1.3× 41 1.1× 11 0.3× 15 262
Katelyn J Cullen United Kingdom 8 254 1.4× 185 1.5× 56 1.2× 64 1.7× 8 0.2× 13 319
Linda Agyemang United States 11 258 1.4× 267 2.1× 33 0.7× 116 3.1× 34 1.0× 21 353
Julien Emmanuelli France 8 307 1.7× 167 1.3× 131 2.8× 98 2.6× 14 0.4× 18 356
Donald Gardenier United States 9 146 0.8× 140 1.1× 18 0.4× 60 1.6× 57 1.6× 62 246
Anna Conway Australia 7 95 0.5× 75 0.6× 25 0.5× 35 0.9× 19 0.5× 23 139
Daniel Raymond United States 3 155 0.8× 135 1.1× 24 0.5× 42 1.1× 21 0.6× 6 184
Julia Fleming United States 6 111 0.6× 87 0.7× 20 0.4× 114 3.1× 8 0.2× 16 224
Fenella Beynon United Kingdom 8 111 0.6× 41 0.3× 13 0.3× 81 2.2× 33 0.9× 14 206

Countries citing papers authored by Eberhard Schatz

Since Specialization
Citations

This map shows the geographic impact of Eberhard Schatz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eberhard Schatz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eberhard Schatz more than expected).

Fields of papers citing papers by Eberhard Schatz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eberhard Schatz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eberhard Schatz. The network helps show where Eberhard Schatz may publish in the future.

Co-authorship network of co-authors of Eberhard Schatz

This figure shows the co-authorship network connecting the top 25 collaborators of Eberhard Schatz. A scholar is included among the top collaborators of Eberhard Schatz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eberhard Schatz. Eberhard Schatz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Noori, Teymur, Marı́a Buti, Asunción Díaz, et al.. (2022). Monitoring progress towards elimination of hepatitis B and C in the EU/EEA. SHILAP Revista de lepidopterología. 2(8). e0000841–e0000841. 4 indexed citations
2.
Schatz, Eberhard, et al.. (2021). Civil society involvement in harm reduction drug policy: reflections on the past, expectations for the future. Harm Reduction Journal. 18(1). 17–17. 4 indexed citations
3.
Tammi, Tuukka, et al.. (2021). Harm reduction in Europe: a framework for civil society-led monitoring. Harm Reduction Journal. 18(1). 3–3. 7 indexed citations
4.
Lazarus, Jeffrey V., et al.. (2020). Novel health systems service design checklist to improve healthcare access for marginalised, underserved communities in Europe. BMJ Open. 10(4). e035621–e035621. 20 indexed citations
5.
Roux, Perrine, et al.. (2020). Implementation and evaluation of an educational intervention for safer injection in people who inject drugs in Europe: a multi-country mixed-methods study. International Journal of Drug Policy. 87. 102992–102992. 9 indexed citations
6.
Matičič, Mojca, Ruth Zimmermann, Marie Jauffret‐Roustide, et al.. (2020). The civil society monitoring of hepatitis C response related to the WHO 2030 elimination goals in 35 European countries. Harm Reduction Journal. 17(1). 89–89. 12 indexed citations
7.
Torrens, Marta, et al.. (2020). Beyond clinical outcomes: the social and healthcare system implications of hepatitis C treatment. BMC Infectious Diseases. 20(1). 702–702. 12 indexed citations
8.
9.
Lazarus, Jeffrey V., et al.. (2019). Nobody Left Outside (NLO) Checklist: Improving access to healthcare for vulnerable and underserved groups. International Journal of Integrated Care. 19(4). 507–507. 2 indexed citations
10.
Pericàs, Juan M., Daniel J. Bromberg, Eberhard Schatz, et al.. (2019). Hepatitis C services at harm reduction centres in the European Union: a 28-country survey. Harm Reduction Journal. 16(1). 4 indexed citations
11.
Běláčková, Vendula, Allison M. Salmon, Eberhard Schatz, & Marianne Jauncey. (2018). Drug consumption rooms (DCRs) as a setting to address hepatitis C – findings from an international online survey. PubMed. 3(1). 9–9. 25 indexed citations
12.
Lazarus, Jeffrey V., Kelly Safreed‐Harmon, Marie Jauffret‐Roustide, et al.. (2017). Restrictions on access to direct-acting antivirals for people who inject drugs: The European Hep-CORE study and the role of patient groups in monitoring national HCV responses. International Journal of Drug Policy. 47. 47–50. 16 indexed citations
13.
Lazarus, Jeffrey V., Kelly Safreed‐Harmon, Massimo Colombo, et al.. (2017). Many European countries 'flying blind' in their efforts to eliminate viral hepatitis. Nature Reviews Gastroenterology & Hepatology. 14(8). 445–446. 4 indexed citations
14.
Mauss, Stefan, Stanislas Pol, Marı́a Buti, et al.. (2017). Late presentation of chronic viral hepatitis for medical care: a consensus definition. BMC Medicine. 15(1). 92–92. 36 indexed citations
15.
Schatz, Eberhard, Janet Seeley, Joel Negin, J. Mugisha, & Helen A. Weiss. (2017). LEAVING NO ONE BEHIND: SUPPORTING ART ACCESS AND ADHERENCE AMONG OLDER UGANDANS LIVING WITH HIV. Innovation in Aging. 1(suppl_1). 750–750. 1 indexed citations
16.
Běláčková, Vendula, Allison M. Salmon, Eberhard Schatz, & Marianne Jauncey. (2017). Online census of drug consumption rooms (DCRs) as a setting to address HCV: current practice and future capacity.. 4 indexed citations
17.
Schatz, Eberhard, et al.. (2016). The Berlin Hepatitis C Manifesto: access to prevention, testing, treatment and care for people who use drugs. PubMed. 1(1). 14–14. 5 indexed citations
18.
Schatz, Eberhard, et al.. (2012). IDPC Briefing Paper - Drug Consumption Rooms: Evidence and Practice. SSRN Electronic Journal. 9 indexed citations
19.
20.
Schatz, Eberhard, et al.. (2008). Empowerment and self – organisations of drug users: experiences and lessons learnt.. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Martin Kåberg Breakdown of academic impact, for papers by Anna Palmer Breakdown of academic impact, for papers by Katelyn J Cullen Breakdown of academic impact, for papers by Linda Agyemang Breakdown of academic impact, for papers by Julien Emmanuelli Breakdown of academic impact, for papers by Donald Gardenier Breakdown of academic impact, for papers by Anna Conway Breakdown of academic impact, for papers by Daniel Raymond Breakdown of academic impact, for papers by Julia Fleming Breakdown of academic impact, for papers by Fenella Beynon
Rankless by CCL
2026